|Budget Amount *help
¥19,500,000 (Direct Cost: ¥15,000,000、Indirect Cost: ¥4,500,000)
Fiscal Year 2011: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2010: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2009: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2008: ¥9,230,000 (Direct Cost: ¥7,100,000、Indirect Cost: ¥2,130,000)
We performed phase I clinical peptide vaccination trials for patients with disseminated synovial sarcoma or osteosarcoma. For synovial sarcoma, the trial was completed and the safety and efficacy of SYT-SSX peptide vaccination was confirmed. For osteosarcoma, the trial is continued.
We identified cancer-stem like cells from malignant fibrous histiocytoma of the bone and epithelial sarcoma. Furthermore, we established autologous cytotoxic T-lymphocyte clone recognizing cancer-stem like cells in the context of HLA class I. These observations open the door toward immunotherapy targeting cancer-stem like cells.